Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Operating Expenses (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Operating Expenses for 9 consecutive years, with $137.4 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 5.79% to $137.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $555.3 million through Dec 2025, up 10.65% year-over-year, with the annual reading at $555.3 million for FY2025, 10.65% up from the prior year.
  • Operating Expenses for Q4 2025 was $137.4 million at Denali Therapeutics, roughly flat from $137.4 million in the prior quarter.
  • The five-year high for Operating Expenses was $156.0 million in Q1 2023, with the low at $79.1 million in Q1 2021.
  • Average Operating Expenses over 5 years is $118.9 million, with a median of $119.9 million recorded in 2024.
  • The sharpest move saw Operating Expenses soared 43.55% in 2023, then fell 15.2% in 2024.
  • Over 5 years, Operating Expenses stood at $89.6 million in 2021, then increased by 29.0% to $115.6 million in 2022, then grew by 14.65% to $132.6 million in 2023, then decreased by 2.06% to $129.8 million in 2024, then grew by 5.79% to $137.4 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $137.4 million, $137.4 million, and $135.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.